ArticleRespiratory research2021

Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation.

Changhui Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.